Omniscan (Gadodiamide)

Gadodiamide, the active ingredient in Omniscan, is a contrast media presented as a 0.5 ml/0.5 mmol injection for intravenous use. It enhances magnetic resonance imaging (MRI) scans, helping radiologists visualize vascular structures and tissue differences in adult and pediatric patients. GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide.

GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide.

Omniscan is a gadolinium‑based MRI contrast agent used to improve diagnostic imaging of several body systems.

- Central nervous system imaging: improves lesion detection and delineation in brain and spinal cord studies. - Cardiovascular imaging: enhances visualization of cardiac chambers, vessels and myocardial perfusion. - Abdominal and pelvic imaging: clarifies lesions in liver, kidneys, pancreas and the reproductive organs. - Angiographic studies: provides high‑contrast definition of arterial and venous structures. - Whole‑body screening: assists in detecting metastatic disease and systemic pathology.

Adverse reactions to Omniscan are generally uncommon but can range from mild to severe.

Common Side Effects: - Nausea: transient feeling of stomach upset. - Headache: mild to moderate intensity. - Injection site discomfort: pain or burning at the infusion site. - Warm sensation: brief feeling of heat throughout the body. - Dizziness: temporary light‑headedness.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment. - Anaphylactoid reaction: sudden onset of hives, swelling, or breathing difficulty. - Severe hypersensitivity: rash, bronchospasm, or hypotension requiring medical intervention. - Cardiac arrest: extremely rare but life‑threatening event. - Renal toxicity: worsening kidney function in susceptible individuals.

Omniscan should be administered only after evaluating patient history and renal function.

- Assess renal function: check eGFR before use, especially in patients with known kidney disease. - Avoid in severe renal impairment: contraindicated when eGFR <30 ml/min/1.73 m². - Monitor for allergic reactions: observe patients during and after injection for signs of hypersensitivity. - Use lowest effective dose: limit gadolinium exposure to the minimum required for diagnostic quality. - Pregnancy and lactation: weigh benefits against potential risks; use only if essential. - Store at ambient temperature: keep below 25 °C, protect from light, and retain in original packaging.

Gadodiamide may interact with other agents that affect renal function or cause hypersensitivity.

Major Interactions (Avoid): - Loop diuretics: can exacerbate renal insufficiency, increasing NSF risk. - High‑dose intravenous iron: may compete for protein binding and alter gadolinium clearance.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce renal perfusion, requiring closer monitoring of kidney function. - Metformin: assess renal function before use; adjust dosing if significant impairment is detected. - Other gadolinium agents: avoid sequential administration to prevent cumulative gadolinium load. - Radiopharmaceuticals: monitor for additive contrast effects in combined imaging studies.